Invasive Candidiasis clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases
open to eligible people ages 18 years and up
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
at UC Davis
A Study of Experimental Rezafungin Compared to Caspofungin For Candidemia and/or Invasive Candidiasis (yeast infection in blood)
Sorry, in progress, not accepting new patients
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
at UC Davis
Last updated: